1. Clinical Gastroenterology and Hepatology
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases 
Joseph Meserve, Satimai Aniwan, Jenna L. Koliani-Pace, Preeti Shashi, Aaron Weiss, David Faleck, Adam Winters, Shreva Chablaney, Gursimran Kochhar, Brigid S. Boland, Siddharth Singh, Robert Hirten, Eugenia Shmidt, Justin G. Hartke, Prianka Chilukuri, Matthew Bohm, Sashidhar Varma Sagi, Monika Fischer, Dana Lukin, David Hudesman, Shannon Chang, Youran Gao, Keith Sultan, Arun Swaminath, Nitin Gupta, Sunanda Kane, Edward V. Loftus, Bo Shen, Bruce E. Sands, Jean-Frederic Colombel, Corey A. Siegel, William J. Sandborn, Parambir S. Dulai 
Clinical Gastroenterology and Hepatology 
DOI: /j.cgh
Copyright © 2018 AGA Institute Terms and Conditions

2. Figure 1
Proportions of patients on vedolizumab therapy developing serious adverse events or infections when stratified by concomitant immunosuppressive therapy.
Clinical Gastroenterology and Hepatology DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

3. Figure 2
Proportions of patients on vedolizumab therapy developing infections when stratified by concomitant immunosuppressive (IS) therapy and key treatment history. TNF, tumor necrosis factor.
Clinical Gastroenterology and Hepatology DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

4. Supplementary Figure 1 Flow chart of patient inclusion.
Clinical Gastroenterology and Hepatology DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions